Jonathan S. Coblyn

2.8k total citations · 1 hit paper
34 papers, 2.1k citations indexed

About

Jonathan S. Coblyn is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Jonathan S. Coblyn has authored 34 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Jonathan S. Coblyn's work include Rheumatoid Arthritis Research and Therapies (16 papers), Systemic Lupus Erythematosus Research (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Jonathan S. Coblyn is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Systemic Lupus Erythematosus Research (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Jonathan S. Coblyn collaborates with scholars based in United States, United Kingdom and Switzerland. Jonathan S. Coblyn's co-authors include Michael E. Weinblatt, David N. Glass, Patricia A. Fraser, David A. Fox, David E. Trentham, Donald E. Holdsworth, Agnes L. Maier, Martin E. Hemler, Nancy A. Shadick and Jennie G. Jacobson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Annals of Internal Medicine.

In The Last Decade

Jonathan S. Coblyn

34 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis

1985 705 citations Michael E. Weinblatt, Jonathan S. Coblyn et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan S. Coblyn United States	21	1.2k	466	443	368	265	34	2.1k
Jacques Tébib France	25	1.3k 1.1×	386 0.8×	669 1.5×	246 0.7×	247 0.9×	91	2.3k
A M Boerbooms Netherlands	24	834 0.7×	273 0.6×	363 0.8×	160 0.4×	189 0.7×	59	1.8k
Leena Laasonen Finland	26	1.2k 1.0×	433 0.9×	261 0.6×	220 0.6×	149 0.6×	83	2.4k
Katsuyasu Saigo Japan	20	521 0.4×	609 1.3×	346 0.8×	247 0.7×	238 0.9×	106	1.8k
J O'donnell New Zealand	27	731 0.6×	255 0.5×	380 0.9×	255 0.7×	88 0.3×	62	1.8k
Matija Tomšič Slovenia	28	1.7k 1.4×	606 1.3×	627 1.4×	441 1.2×	259 1.0×	131	2.8k
Rolf Rau Germany	23	2.4k 2.0×	963 2.1×	770 1.7×	394 1.1×	285 1.1×	39	3.3k
Olivier Vittecoq France	36	2.0k 1.6×	547 1.2×	776 1.8×	302 0.8×	462 1.7×	165	3.5k
Scott W. Baumgartner United States	16	1.4k 1.1×	1.0k 2.1×	766 1.7×	232 0.6×	264 1.0×	18	2.5k
Martina Biggioggero Italy	23	1.1k 0.9×	362 0.8×	555 1.3×	205 0.6×	195 0.7×	69	1.7k

Countries citing papers authored by Jonathan S. Coblyn

Since Specialization

Citations

This map shows the geographic impact of Jonathan S. Coblyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan S. Coblyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan S. Coblyn more than expected).

Fields of papers citing papers by Jonathan S. Coblyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan S. Coblyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan S. Coblyn. The network helps show where Jonathan S. Coblyn may publish in the future.

Co-authorship network of co-authors of Jonathan S. Coblyn

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan S. Coblyn. A scholar is included among the top collaborators of Jonathan S. Coblyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan S. Coblyn. Jonathan S. Coblyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Das, Priyam, Dana Weisenfeld, Jonathan S. Coblyn, et al.. (2023). Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis. Arthritis Research & Therapy. 25(1). 93–93. 4 indexed citations

Coblyn, Jonathan S.. (2017). Steroid Injections for Knee Osteoarthritis Might Hasten Cartilage Loss. Journal watch. 2017. 1 indexed citations

Coblyn, Jonathan S.. (2016). Do TNF Inhibitors Directly Affect Cardiovascular Risk. Journal watch. 2016. 1 indexed citations

Sparks, Jeffrey A., Jakob I. McSparron, Nehal Shah, et al.. (2014). Osseous sarcoidosis: Clinical characteristics, treatment, and outcomes—Experience from a large, academic hospital. Seminars in Arthritis and Rheumatism. 44(3). 371–379. 60 indexed citations

Ercan, Altan, Jing Cui, Melissa M. Hazen, et al.. (2012). Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Research & Therapy. 14(2). R43–R43. 23 indexed citations

Liao, Katherine P., Michael E. Weinblatt, Jing Cui, et al.. (2011). Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Lara D. Veeken. 50(8). 1473–1479. 20 indexed citations

Agnew‐Blais, Jessica, Jonathan S. Coblyn, Jeffrey N. Katz, et al.. (2008). Measuring quality of care for rheumatic diseases using an electronic medical record. Annals of the Rheumatic Diseases. 68(5). 680–684. 22 indexed citations

Shin, Kichul, Scott R. Granter, Jonathan S. Coblyn, & Samardeep Gupta. (2008). Progressive arm and leg stiffness in a patient with chronic renal impairment. Nature Clinical Practice Rheumatology. 4(10). 557–562. 8 indexed citations

Karlson, Elizabeth W., Lori B. Chibnik, Jing Cui, et al.. (2007). Associations between Human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Annals of the Rheumatic Diseases. 67(3). 358–363. 71 indexed citations

10.

Agarwal, Sandeep K., Paul A. Monach, William P. Docken, & Jonathan S. Coblyn. (2005). Characterization of relapses in adult idiopathic inflammatory myopathies. Clinical Rheumatology. 25(4). 476–481. 6 indexed citations

11.

Costenbader, Karen H. & Jonathan S. Coblyn. (2005). Statin Therapy in Rheumatoid Arthritis. Southern Medical Journal. 98(5). 534–540. 15 indexed citations

12.

Coblyn, Jonathan S. & Robert T. McCluskey. (2003). Case 3-2003. New England Journal of Medicine. 348(4). 333–342. 4 indexed citations

13.

Phillips, Kristine, M. Elaine Husni, Elizabeth W. Karlson, & Jonathan S. Coblyn. (2002). Experience with etanercept in an academic medical center: Are infection rates increased?. Arthritis Care & Research. 47(1). 17–21. 89 indexed citations

14.

Coblyn, Jonathan S., Nancy A. Shadick, & Simon M. Helfgott. (2001). Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis & Rheumatism. 44(5). 1048–1051. 28 indexed citations

15.

Weinblatt, Michael E., Joel M. Kremer, Jonathan S. Coblyn, et al.. (1999). Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis & Rheumatism. 42(7). 1322–1328. 191 indexed citations

16.

Weinblatt, Michael E., Agnes L. Maier, Patricia A. Fraser, & Jonathan S. Coblyn. (1998). Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.. PubMed. 25(2). 238–42. 99 indexed citations

17.

Weinblatt, Michael E., Peter J. Maddison, Ken J. Bulpitt, et al.. (1995). Campath‐1h, a humanized monoclonal antibody, in refractory rheumatoid arthritis. Arthritis & Rheumatism. 38(11). 1589–1594. 93 indexed citations

18.

Weinblatt, Michael E., Bernard F. Germain, Joel M. Kremer, et al.. (1994). Lack of a renal–protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placebo–controlled trial. Arthritis & Rheumatism. 37(9). 1321–1325. 4 indexed citations

19.

Weinblatt, Michael E., et al.. (1986). Cerebral vasculopathy: An analysis of sixteen cases. Seminars in Arthritis and Rheumatism. 15(4). 297–302. 9 indexed citations

20.

Hemler, Martin E., David N. Glass, Jonathan S. Coblyn, & Jennie G. Jacobson. (1986). Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation.. Journal of Clinical Investigation. 78(3). 696–702. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact